Table 4.

Multivariate analysisclinicopathological findings

	5-yr disease free survival			5-yr overall survival
	HR	95% CI	P	HR	95% CI	P
Stage	7.83	2.44-25.18	0.001	6.15	1.97-19.2	0.002
Site	1.21	0.66-2.22	0.536	1.22	0.67-2.23	0.510
Size	0.48	0.188-1.27	0.142	0.577	0.22-1.41	0.218
LN ratio	1.68	1.01-2.79	0.043	2.46	1.01-5.94	0.047
LVI	0.79	0.30-2.11	0.650	1.02	0.41-2.52	0.951
IL-6	1.40	0.53-3.66	0.488	1.19	0.45-3.14	0.726
VEGF	1.22	0.77-1.95	0.390	2.11	0.86-5.17	0.102
SAA	3.21	0.96-10.79	0.058	3.39	1.02-11.23	0.045
CEA	2.17	0.66-7.07	0.198	2.38	0.76-7.48	0.135
CA19-9	0.93	0.35-2.45	0.898	1.96	0.76-5.02	0.158
NF-κB RelA	2.87	0.96-8.49	0.057	3.40	1.17-9.87	0.024

LVI: Lymphovascular invasion; IL-6: Interleukin-6; VEGF: Vascular endothelial growth factor; SAA: Serum amyloid A; LN: Lymph node; CEA: Carcinoembryonic antigen; NF-κB: Nuclear factor-κB; CA19-9: Carbohydrate antigen 19-9; HR: Hazard ratio; 95% CI: 95% confidence interval.